# Humanigen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/humanigen

- Industry: Biotechnology
- Headquarters: Burlingame, US
- Website: www.humanigen.com
- Total disclosed funding: $81M
- Latest round: Series E (May 2, 2012)
- Investors on record: 13

## About

Founded in 2001 as KaloBios Pharmaceuticals, Inc., and based in California, US, Humanigen, Inc. (Nasdaq: HGEN) operates as a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies designed for patients with difficult-to-treat diseases, including respiratory diseases, parasitic infection, and hematologic cancer. 

The company is focused on preventing and treating an immune hyper-response called cytokine storm induced by SARS-CoV-2 (COVID-19) infection through its granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization with lenzilumab, a humaneered® antibody developed by the company.

## Funding rounds

- Series E, May 2, 2012, $17M — Fidelity Investments
- Series D, Sep 23, 2008, $20M — Alloy Ventures, Sofinnova Investments, GBS Venture Partners, 5AM Ventures, MPM BioImpact, Mitsubishi UFJ Capital, Sanofi Ventures, Lotus Biosciences Ventures, Singapore Bio-Innovations
- Series C, Jul 31, 2007, $20M — Alloy Ventures, Sofinnova Investments, GBS Venture Partners, 5AM Ventures, SG Growth Capital, Lehman Brothers, MPM BioImpact, Trilantic Capital Management L.P., Lotus Biosciences Ventures, Singapore Bio-Innovations
- Series B, Mar 16, 2005, $20M — Alloy Ventures, Sofinnova Investments, GBS Venture Partners, 5AM Ventures, MPM BioImpact, Lotus Biosciences Ventures, Singapore Bio-Innovations
- Seed, Jun 24, 2003, $4M — Alloy Ventures, Sofinnova Investments

## Investors

- Alloy Ventures (https://capitalatlas.ai/funds/alloy-ventures) — Seed, Series B, Series C, Series D
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Seed, Series B, Series C, Series D
- GBS Venture Partners (https://capitalatlas.ai/funds/gbs-venture-partners) — Series B, Series C, Series D
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series B, Series C, Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C, Series D
- Lotus Biosciences Ventures (https://capitalatlas.ai/funds/lotus-biosciences-ventures) — Series B, Series C, Series D
- Singapore Bio-Innovations (https://capitalatlas.ai/funds/singapore-bio-innovations) — Series B, Series C, Series D
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series C
- Lehman Brothers (https://capitalatlas.ai/funds/lehman-brothers) — Series C
- Trilantic Capital Management L.P. — Series C
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series D
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series D
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series E